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Abstract 
Bacterial conjugation is a key mechanism by 
which bacteria acquire antibiotic resistance. 
Therefore, conjugation inhibitors (COINs) are 
promising compounds in the fight against the 
spread of antibiotic resistance genes among 
bacteria. Unsaturated fatty acids (uFAs) and 
alkynoic fatty acid derivatives, such as 2-
hexadecanoic acid (2-HDA), were previously 
reported as being effective COINs. The traffic 
ATPase TrwD, a VirB11-homolog in plasmid 
R388, is the molecular target of these compounds, 
which likely affect binding of TrwD to bacterial 
membranes. In this work, we demonstrate that 
COINs are abundantly incorporated into 
Escherichia coli membranes, replacing palmitic 
acid as the major component of the membrane. 
We also show that TrwD binds palmitic acid, thus 
facilitating its interaction with the membrane. Our 
findings also suggest that COINs bind TrwD at a 
site that is otherwise occupied by palmitic acid. 
Accordingly, molecular docking predictions with 
palmitic acid indicated that it shares the same 
binding site as uFAs and 2-HDA, albeit it differs 
in the contacts involved in this interaction. We 
also identified 2-bromopalmitic acid, a palmitate 
analog that inhibits many membrane-associated 
enzymes, as a compound that effectively reduces 
TrwD ATPase activity and bacterial conjugation. 
Moreover, we demonstrate that 2-bromopalmitic 
and palmitic acids both compete for the same 
binding site in TrwD. Altogether, these detailed 
findings open up a new avenue in the search for 
effective synthetic inhibitors of bacterial 
conjugation, which may be pivotal for combating 
multidrug-resistant bacteria.    
 
Introduction 
Bacterial conjugation is one of the main 
mechanisms whereby bacteria become resistant to 
antibiotics (1). Therefore, there is a major interest 
in the search for conjugation inhibitors (COINs). 
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In conjugation, DNA is transferred between two 
bacterial cells through a type IV secretion system 
(T4SS), a multi-subunit complex encoded by the 
conjugative plasmid. Canonical T4SS consists of 
11 proteins, named VirB1 to VirB11, after 
Agrobaterium tumefaciens T4SS (2,3). T4SS 
architecture is well preserved in most conjugative 
bacteria, consisting of four distinct sections: the 
pilus, the core channel complex, the inner 
membrane platform and the ATPases that provide 
the energy for substrate transport and pilus 
biogenesis (4). COINs have been proposed to 
target essential components of the T4SS (5). 
Promising results have been obtained with 
unsaturated fatty acids (uFAs), which specifically 
inhibit plasmid conjugation without inhibiting 
Escherichia coli growth (6,7). The traffic ATPase 
TrwD, the VirB11 homolog in plasmid R388, was 
shown to be the target for this inhibition by uFAs 
(8). TrwD contributes to pilus biogenesis and 
DNA translocation (9), thus working as a 
molecular switch between pilus synthesis and 
substrate transport (10). TrwD was specifically 
inhibited in vitro by the same uFAs and alkynoic 
fatty acid derivatives (2-aFAs) that inhibited 
bacterial conjugation in vivo, such as linoleic acid 
or 2-hexadecynoic acid (2-HDA), respectively. 
These compounds acted as non-competitive 
inhibitors, with no effect on the affinity of the 
protein for ATP or ADP substrates (8). In contrast, 
saturated fatty acids, such as palmitic acid, 
showed no inhibitory effect in conjugation 
experiments (6) and in ATPase assays (8). 
 
TrwD belongs to the secretion ATPase 
superfamily, which also includes members of 
Type II secretion, Type IV pilus and flagellar 
biogenesis machineries (11). All members of this 
superfamily are hexameric ATPases, in which 
each monomer is formed by two domains at the 
N- and C- termini (NTD and CTD, respectively), 
connected by a flexible linker of variable length 
(11,12).  ATPase catalysis is driven by swapping 
the NTD over the CTD, due to the flexibility of 
the linker (13,14).  Blind docking predictions 
suggested a putative binding site for uFAs and 2-
aFAs located at the end of the NTD and beginning 
of the linker region that connects it to the CTD, 
where the nucleotide binding site is located (8). 
These predictions are compatible with a model in 
which the mode of action of the inhibitors 
consisted in preventing the swapping movements 
between the N- and C- terminal domains that are 
required in the catalytic cycle of the protein. 
VirB11 ATPases interact with the cytoplasmic 
site of the membrane through its N-terminal 
domain (15,16). Therefore, it is likely that the 
inhibitory effect of uFAs and 2-aFAs occurs by 
affecting the membrane binding capability of 
TrwD. In this work, we demonstrate that the 2-
alkynoic fatty acid 2-HDA incorporates into 
bacterial membranes, replacing palmitic acid as 
the major component of the membrane. We also 
show that TrwD binds palmitic acid, which 
suggests that uFAs and 2-AFAs act as inhibitors 
by binding TrwD at a site that is otherwise 
occupied by palmitic acid. Accordingly, docking 
predictions with palmitic acid indicate that it 
shares the same binding site as linoleic acid and 2-
HDA. 
 
Interestingly, we also discovered that 2-
bromopalmitic acid (2-BP), a proven compound 
to block palmitate incorporation onto a variety of 
membrane-associated eukaryotic proteins (17), is 
also an inhibitor of TrwD ATPase activity and 
bacterial conjugation. Moreover, we demonstrate 
that 2-bromopalmitic and palmitic acids compete 
for the same binding site in TrwD, as shown by 
the increase in the value of the apparent inhibition 
constant in the presence of the saturated fatty acid. 
Recently, tanzawaic acids also appeared as a 
novel group of bacterial conjugation inhibitors 
(18). All these compounds share similar chemical 
characteristics: a carboxylic group, a long 
unsaturated aliphatic chain and the presence of 
double or triple bonds. The finding of 2-BP as an 
effective inhibitor allows us to conclude that 
inhibition does not occur by the presence of 
double or triple bonds in these compounds but by 
the conformation these fatty acids acquire upon 
TrwD binding. These new findings open a new 
avenue in the search of new and more effective 
synthetic inhibitors by structure-based drug 
design methods.  
 
Results 
2-Alkynoic fatty acids incorporate into bacterial 
membranes, where they exert an inhibitory effect 
on conjugation. 












 Unsaturated fatty acids (uFAs) and 2-alkynoic 
fatty acids specifically inhibit plasmid 
conjugation without inhibiting E. coli growth 
(6,7). Recently, we identified TrwD, the VirB11 
homolog in plasmid R388, as their molecular 
target (8). As VirB11 traffic ATPases transiently 
interact with the cytoplasmic site of the membrane 
(19), 2-alkynoic fatty acids, such as 2-HDA, 
might be incorporated into the bacterial 
membrane to exert an inhibitory conjugation 
effect.  
In an attempt to find out if fatty acid derivatives 
that act as inhibitors (COINs) do incorporate into 
membranes, E. coli cells were grown in the 
presence and absence of the inhibitor 2-HDA. 
After 18 h incubation, the composition in 
esterified fatty acids (FAMEs) from membrane 
phospholipids and free fatty acids was checked by 
Gas Chromatography-Mass Spectrometry (GC-
MS). Results revealed that the phospholipid fatty 
acids present in untreated bacteria are primarily 
saturated, being palmitic acid (16:0) the most 
abundant (almost 50% of the total membrane 
phospholipids contained palmitic acid) (Figure 1). 
When cells were grown in the presence of 2-HDA 
(50 µg/ml), bacteria incorporated this exogenous 
fatty acid to their membranes. Moreover, the 
major component of the total phospholipids in 
treated bacteria was 2-HDA (44% w/w). The 
incorporation of 2-HDA into the bacterial 
membrane was accompanied by a 2-fold decrease 
of palmitic acid in the phospholipid fraction. In 
contrast, the percentage of palmitic acid in the free 
fatty acid fraction was not significantly altered 
when cells were treated with 2-HDA (Figure 1). 
As result of this experiment, we conclude that 
incorporation of 2-HDA into the bacterial 
membrane alters the utilization of endogenous 
fatty acids in the biosynthesis of phospholipids, 
with a significant amount of palmitic acid being 
replaced by 2-HDA in the bacterial membrane.  
 
TrwD binds palmitic acid 
The surprising effect observed in the previous 
experiment suggested that such a replacement 
might in turn affect the association of TrwD to the 
membrane. In contrast to uFAs or 2-HDA, 
saturated fatty acids neither inhibit bacterial 
conjugation (6), nor TrwD ATPase activity in 
vitro (8). Nonetheless, docking predictions with 
palmitic acid suggested that its binding site is the 
same as that for uFAs and 2-HDA, albeit adopting 
a different conformation due to the lack of double 
or triple bonds (8).  
The molecular bases that underlie TrwD binding 
to the membrane are unknown. Therefore, we 
investigated a possible lipid-protein association 
via palmitic acid, by studying the binding of 
TrwD to 14C-labeled palmitic acid. Purified TrwD 
protein was incubated with palmitic acid at 
different ratios, and samples were analyzed by 
polyacrylamide gel electrophoresis under non-
denaturing conditions (Figure 2A). Radiolabeling 
of TrwD with palmitic acid was directly related to 
increasing palmitate/protein ratios. As control, 
TrwA protein (a conjugative protein that does not 
bind to the membrane) was incubated with 14C-
labeled palmitic acid at the highest palmitic 
acid/protein ratio. No radioactivity signal was 
observed for this control protein. Similar 
experiments, carried out with 14C-labeled 
palmitoyl-CoA, gave identical results. In this 
latter case, it was possible to observe the unbound 
labeled palmitoyl-CoA running at the front of the 
gel (Figure 2B).  
 
S-palmitoylation, a covalent attachment of fatty 
acids to cysteine residues of proteins,  enhances 
the surface hydrophobicity and membrane affinity 
of proteins, playing an important role in 
modulating protein trafficking (20). TrwD 
contains five cysteine residues in its sequence, 
with one of them placed at the N-terminal domain 
(Cys44). Although this is a post-translational 
modification observed in eukaryotic proteins, we 
wanted to check if TrwD was covalently bound to 
palmitic acid. The association of labeled palmitate 
with TrwD was sensitive to denaturation induced 
by SDS gel electrophoresis, which suggests that 
the binding is non-covalent and there is no 
thioester bond involved in such association. 
 
2-Bromopalmitic acid inhibits TrwD ATPase 
activity  
2-Bromopalmitic acid (2-BP) is a palmitate 
analog that acts as inhibitor of many membrane-
associated enzymes (17). It is an irreversible 
inhibitor that blocks palmitate incorporation onto 












proteins. The exact mechanism responsible for 2-
BP mediated inhibition is not known. It is thought 
to inhibit protein acyl-transferases (21), but recent 
reports showed that 2-BP is a non-selective probe, 
with many other different targets (22).  
 
Thus, we analyzed the ATPase activity of TrwD 
in the presence of increasing concentrations of 2-
BP (Figure 3). Analysis of the kinetics showed an 
inhibition pattern similar to 2-HDA or unsaturated 
fatty acids. In all cases, data did not fit to a 
Michaelis-Menten inhibition kinetic curve, but to 
a sigmoidal Hill equation, which suggested a 
cooperative effect in the inhibition kinetics. The 
apparent inhibition constant [Ki(app)] of 2-
bromopalmitic acid was 21.5 ± 1.5 µM, similar to 
that obtained for 2-HDA [Ki(app)= 29.7±2.1µM] 
(Figure 3).  
 
Previously discovered conjugation inhibitors 
(COINs), such as uFAs (oleic and linoleic acids), 
chemically synthesized 2-HDA and derivatives 
(7) or tanzawaic acids (18), shared similar 
chemical characteristics: a carboxylic group, a 
long unsaturated aliphatic chain and the presence 
of double or triple bonds. The finding that 2-BP is 
an effective inhibitor was at first surprising. 
Nevertheless, the results shown above allow us to 
conclude that inhibition does not occur by the 
presence of double or triple bonds in these 
compounds but, indirectly, by the conformation 
these fatty acids acquire when bound to TrwD. 
Docking predictions with 2-BP indicate that the 
binding site for the palmitic acid analog is also in 
the same region as linoleic acid, 2-HDA and 
palmitic acid (Figure 4). In this case, the presence 
of a halogen group (2-bromo) within the saturated 
fatty acid can result in a similar inhibitory effect, 
but modifying the mode of binding. 
 
2-bromopalmitic and palmitic acids compete for 
the same binding site in TrwD 
To determine if 2-bromopalmitic and palmitic 
acids compete for the same binding site, we 
conducted a further characterization of the 
mechanism of inhibition. ATP turnover was 
measured at increasing concentrations of 2-BP in 
the presence of palmitic acid (500 µM) (Figure 5). 
Under these experimental conditions, the apparent 
inhibition constant [Ki(app)] of 2-BP increased 3-
fold (from 21.5 ± 1.5 µM to 65.4 ± 1.4 µM)  
(Figure 3), suggesting that palmitic acid and 2-BP 
compete for the same binding site in TrwD.  
 
2-Bromopalmitic acid inhibits R388 conjugation 
In a previous work (8), we observed that 2-
alkynoic fatty acids that inhibited bacterial 
conjugation, such as 2-hexadecynoic acid (2-
HDA), 2-octadecynoic acid (2-ODA) or 2,6-
hexadecadiynoic acid (2,6-HDA), also inhibited 
TrwD ATPase activity in vitro. In contrast, those 
with no effect in vivo, such as alcohol or 
tetrahydropyranyl-ether derivatives, did not affect 
the in vitro TrwD ATPase activity either. 
Therefore, once we discovered that 2-BP was an 
effective inhibitor of TrwD ATPase activity, we 
checked if this compound was also an inhibitor of 
bacterial conjugation. R388 conjugation 
frequencies at increased concentrations of 2-BP 
are shown in Figure 6.  
Bacterial conjugation was monitored by a high-
throughput assay based on fluorescence emission 
by transconjugant cells. Control assays were 
carried out to discard any effect on bacterial 
growth or plasmid stability. Addition of 2-BP (0.3 
mM) resulted in the inhibition of R388 
conjugation (Figure 6). 2-BP inhibited R388 
conjugation to levels similar to those obtained 
with 2-HDA (to about 2 % of the control without 
COIN). Moreover, when palmitic acid (500 µM) 
was added to the conjugation media, a higher 
concentration of 2-BP was required to reach a 
similar inhibitory effect. This result perfectly 
correlates with that obtained in vitro, on TrwD 





VirB11 proteins belong to a large family of 
hexameric AAA+ traffic ATPases, which 
includes proteins involved in Type II secretion 
and in Type IV pilus and flagellar biogenesis (11). 
VirB11 from Agrobacterium tumefaciens 
localized at the cell pole, as shown by 
epifluorescence microscopy of a GFP-VirB11 
fusion protein (23). The protein required neither 
ATP nor other VirB proteins for its polar 
localization (19). In contrast, in the presence of a 












complete T4SS machinery, VirB11 localized all 
over the bacterial cell perimeter (24). 
Accordingly, in vitro experiments had previously 
shown that TrwD, the VirB11 homolog in plasmid 
R388, interacts with phospholipids in lipid 
vesicles, causing lipid vesicle aggregation and 
intervesicular lipid mixing, supporting the 
hypothesis that TrwD also behaves as a 
membrane-associated  protein (16). Therefore, 
although it is proved that the protein localizes in 
the bacterial inner membrane, the molecular bases 
underlying this interaction with membrane lipids 
were unknown. 
 
Recently, we identified TrwD as the molecular 
target for fatty acid-mediated inhibition of 
conjugation (8), showing that unsaturated fatty 
acids (uFAs) and 2-alkynoic fatty acids (aFAs) 
that inhibited bacterial conjugation, such as 2-
HDA, 2-ODA or 2,6-HDA, also inhibited TrwD 
ATPase activity. In contrast, saturated fatty acids 
such as palmitic acid, neither showed an 
inhibitory effect in conjugation experiments nor in 
ATPase assays. In an attempt to explain how these 
compounds can act as inhibitors of bacterial 
conjugation, we investigated the putative 
interaction of uFAs and aFAs with the bacterial 
membrane.  Indeed, our results revealed that the 
phospholipid fatty acids present in untreated 
bacteria are mainly saturated, being palmitic acid 
the most abundant. However, when cells were 
grown in the presence of 2-HDA, this compound 
was incorporated into the membrane and became 
the major component of the total phospholipid 
fraction (Figure 1). More importantly, a 
significant amount of palmitic acid was replaced 
by 2-HDA in the membrane. Therefore, it was 
reasonable to think that this replacement of 
palmitic acid by fatty acids with double or triple 
bonds might be responsible of such an inhibitory 
effect. Thus, we wondered whether TrwD 
interaction with the membrane was occurring via 
palmitic acid under normal growth conditions. 
Supporting this idea, a blind docking search of the 
palmitic acid in TrwD structure revealed the same 
binding site as for uFAs and 2-HDA, albeit it 
differs in the contacts involved in the interaction 
(8). To confirm the putative binding of saturated 
fatty acids, purified TrwD protein was incubated 
with 14C-labeled palmitic acid and the resulting 
complex was analyzed in native gels (Figure 2). 
Radiolabeling of TrwD with palmitic acid was 
directly related to increasing palmitate/protein 
ratios. 
 
A wide variety of proteins associate to the 
membrane by a covalent attachment to palmitic 
acid (20). In these palmitoylated proteins, the fatty 
acid is bound to a cysteine residue through a 
thioester linkage. This is a reversible process that 
allows a transient binding to the membrane, which 
is crucial in many biological processes. This lipid 
modification is common in eukaryotic cells (20) 
but is poorly documented in prokaryotes. To our 
knowledge, there is only one example of S-
palmitoylation for a bacterial protein (25). TrwD 
presents five cysteine residues. One of them is 
placed at the NTD, so palmitoylation might be a 
possible mechanism of interaction of TrwD with 
the membrane. Therefore, we checked if the 
association of radio-labeled palmitate with TrwD 
was resistant to denaturation induced by SDS gel 
electrophoresis. No signal of radiolabeled protein 
was observed in these gels. Samples of purified 
protein incubated with palmitic acid were also 
analyzed by mass spectrometry, but no difference 
in molecular mass was observed when the sample 
was compared to a control in the absence of the 
fatty acid. Therefore, our data indicate that the 
binding to palmitic acid is non-covalent, 
excluding the possibility that the association of 
palmitate with TrwD is due to protein 
palmitoylation. In the literature, there are also 
several examples of proteins that associate to the 
membrane via a non-covalent binding to saturated 
fatty acids, such as Toll-like receptors (TLRs) 
(26).  In this case, the polyunsaturated fatty acid 
binds to a lipid binding pocket in the protein 
receptor. Intriguingly, TLRs are also inhibited by 
polyunsaturated fatty acids (27), as in the case of 
TrwD. 
 
To study the binding of palmitic acid to TrwD, we 
explored the binding capacity of an analog, 
namely 2-bromopalmitic acid (2-BP). This fatty 
acid was found to act as inhibitor of many 
membrane-associated enzymes that bind palmitic 
acid (17). First, we checked if this palmitate 
analog also inhibited TrwD activity. We analyzed 
the ATPase activity of the protein in the presence 
of increasing concentrations of 2-BP (Figure 3). 
The inhibition pattern was similar to that obtained 












with 2-HDA or uFAs, with an apparent inhibition 
constant similar to that obtained for 2-HDA. In a 
previous work, we found that the same fatty acid 
derivatives that were effective inhibitors of 
bacterial conjugation were also capable of 
inhibiting TrwD ATPase activity, and vice versa, 
those unable to inhibit conjugation also failed to 
inhibit TrwD activity, with a perfect correlation 
between the in vivo and in vitro data (8). In the 
same way, in this work we demonstrate that 2-BP 
inhibited R388 conjugation, as in the case of 2-
HDA (Figure 6). Moreover, when palmitic acid 
was added to the conjugation media, a higher 
concentration of 2-BP was required to reach a 
similar inhibitory effect. This effect is probably 
due to the incorporation of 2-BP into the bacterial 
membrane and the consequent replacement of 
palmitic acid by 2-BP, an effect that has already 
been observed for 2-HDA (Figure 1). Therefore, 
these inhibitors seem to act by displacing the more 
abundant saturated acid in the membrane.  
 
In an attempt to determine if 2-BP and palmitic 
acid compete for the same binding site in TrwD, 
ATP turnover was measured at increasing 
concentrations of 2-BP in the presence of palmitic 
acid (Figure 5). The apparent inhibition constant 
(Ki(app)) of 2-BP raised from 21.5 ± 1.5 µM to 
65.4 ± 1.4 µM (Figure 3), which suggests that both 
fatty acids (palmitic acid and 2-BP) compete for 
the same binding site in TrwD. Although it is 
generally accepted that 2-BP blocks S-
palmitoylation by inhibiting protein acyl 
transferases (21), recent work has shown that 2-
BP has many other targets, leading the authors to 
suggest that the compound might exert the 
inhibition by direct competition with palmitic acid 
(22). The results obtained with TrwD in this work 
agree with this hypothesis and might be extensive 
to proteins that associate with the inner membrane 
via interaction with palmitic acid. 
 
In summary, in this work we describe 2-BP, a 
palmitate analog, as a new inhibitor of bacterial 
conjugation. As previously described inhibitors, 
which are also fatty acid derivatives, 2-BP acts on 
the traffic ATPase TrwD as its molecular target. 
The results presented here demonstrate that 
inhibitors such as 2-HDA, incorporate into the 
bacterial membrane and replace a significant 
fraction of palmitic acid. Although it was known 
that VirB11 proteins localize in the bacterial inner 
membrane, the molecular bases of this interaction 
had not been identified. We have proven that 
TrwD interacts with palmitic acid, which suggests 
TrwD interacts with the membrane by binding this 
fatty acid. This work shows that COINs act by 
competing with palmitic acid for the same binding 
site in TrwD. Moreover, fatty acid derivatives 
lacking the carboxylic group do not inhibit the 
protein but are still predicted to bind to the same 
pocket, albeit with different protein contacts 
(Ripoll-Rozada, et al, 2016), reinforcing the 
importance of the stereospecificity of the binding 
in order to exert the inhibition.  These differences 
in the mode of binding might explain the different 
behavior of palmitic acid and the fatty acid 
derivatives that act as inhibitors, such as 2-BP 
(Figure 4). In the latter case, the bromine 
substituent induces a different conformation in the 
carboxylic group, which is forced to move 120 
degrees apart, creating closer contacts with basic 
residues of the flexible linker. This linker plays an 
essential role in ATP catalysis, allowing the 
movement of the N-terminal domain (NTD) over 
the C-terminal domain (CTD) (13,14). In contrast, 
binding predictions for palmitic acid locate its 
carboxylic group in the opposite direction, out of 
the linker region. These differences might explain 
why the presence of the bromide ion or double and 
triple bonds in the fatty acid derivatives that act as 
inhibitors affect the catalytic mechanism of 
TrwD.  
 
It is worth noting that uFAs and 2-aFAs are 
effective inhibitors of IncW plasmids such as 
R388, but other plasmid groups, such as IncN and 
IncP, are not affected by them (6,7).  In contrast 
to TrwD, TrbB, its homolog in RP4 plasmid 
contains a much shorter linker, being more similar 
to HP0525 (H. pylori) than to VirB11 (Ripoll-
Rozada, 2013). Likewise to HP0525, TrbB does 
not have a pocket between the linker and the NTD, 
and therefore, it is not surprising to observe a lack 
of effect of COINs in this system. By contrast, 
VirB11 homologs from IncN plasmids are close 
TrwD relatives. However, plasmids from this 
group, such as pKM101, are not inhibited by these 
COINs, either.   A close inspection of TraG 
structure, the VirB11 homolog in plasmid 
pKM101, revealed substantial differences with 
TrwD. The equivalent binding site in TraG 












presents a different global charge balance and is 
occluded by two hydrophobic residues, which 
gives no room for fatty acid binding (Figure 1S). 
Moreover, docking predictions in TraG with 2-BP 
and 2-HDA indicate that the binding site for these 
fatty acids is in a different region (Figure 2S). This 
binding site is also at the NTD, but it does not 
involve the linker and, therefore, it does not affect 
the catalytic mechanism of the enzyme, which 
might explain the lack of inhibition of TraG by 
these fatty acid derivatives. These new findings 
will allow us to optimize the chemical structure of 
these compounds by structure-based drug design 
methods, in order to design new and more 
effective derivatives that act as COINs.  
 
Experimental procedures 
Proteins and fatty acids. Cloning, overexpression 
and purification of TrwD and TrwA proteins were 
carried out as described previously (28,29). 
Palmitic and 2-bromopalmitic acids were 
purchased from Sigma-Aldrich. Palmitic acid 
derivatives, such as [14C(U)] and palmitoyl-
Coenzyme A, [Palmitoyl-1-14C] were purchased 
from PerkinElmer. 2-HDA was synthesized as 
previously described (30). 
Gas Chromatography-Mass Spectrometry (GC-
MS). E. coli ATCC 25922 (American Type 
Culture Collection, Manassas, VA) was grown in 
Luria-Bertani broth (LB, Lennox, Fisher 
Scientific, Fair Lawn, NJ) medium in the presence 
and absence of 2-HDA (50 µg/mL) at 37˚C for 18 
h. Then, cells were collected, extracted by using 
15 mL of chloroform:methanol (2:1, v/v), shaken 
(Labnet, Edison, NJ) for 30 min at 200 rpm, and 
sonicated into Ultrasonic Cleaner (Fisher Brand 
FB11201, Germany) at 37 kHz (100 % power, 390 
W) for 15 min at room temperature. Phospholipids 
and free fatty acids were separated from total 
lipids by using silica gel column chromatography. 
Free fatty acids were eluted by adding 15 mL of 
acetone, while phospholipids were eluted by 
adding 15 mL of hexane. Solvents from both 
acetone and hexane fractions were removed by 
rotoevaporation (Büchi, Rotavapor R-114, 
Switzerland) and the resulting lipid content was 
treated with 3 mL of methanol and 150 µl of 12 M 
HCl and subsequently refluxed for 3 h. Once the 
transesterification reaction was completed, 
methanol was removed by rotoevaporation and 
fatty acid methyl esters (FAMEs) were analyzed 
by using GC-MS (Hewlett Packard Series II MS 
ChemsStation coupled to an Hewlett Packard 
5972 Series Mass Selective Detector equipped 
with a 30 m x 0.25 mm special performance 
capillary column HP-5MS of polymethyl siloxane 
crosslinked with 5 % phenyl methylpolysiloxane). 
The selected temperature method was: 120 °C 
initial temperature, 5 °C/min temperature rate, and 
260 °C final temperature. The split ratio was set at 
10:1 for all analyses. All fatty acids were 
identified based on their molecular ion, base peak, 
fragmentation pattern and retention time and then 
expressed as a percentage of total FAs.    
Radio-labeling assays. Purified proteins were 
incubated with 14C-labeled fatty acids for 10 min 
at room temperature. Then, samples were 
analyzed by native polyacrylamide gel 
electrophoresis (Native-PAGE), following the 
protocol previously described (31). 4.5 % 
polyacrylamide gels were run at pH 8.5 for 140 
min in an ice bath, with a constant amperage (30 
mA). Then, gels were dried, exposed overnight 
and visualized using a Fluoro Image Analyzer 
FLA-5100 (FujiFilm) to detect radiolabeled 
proteins on electrophoretic bands. 
ATP hydrolysis assays. Steady-state ATP 
hydrolysis activity in vitro was measured with the 
EnzCheckTM Kit (Invitrogen) in a UV-1800 
spectrophotometer (Shimadzu), as described 
previously (28). Inorganic phosphate (Pi) released 
after ATP hydrolysis was monitored as an 
increase of absorption at 360 nm for 10 min 
following manufacturer’s instructions and 
components: 0.2 mM 2-amino-6-mercapto-7-
methylpurine riboside (MESG) and 1 unit/ml of 
purine nucleoside phosphorylase (PNP). Fatty 
acids diluted in DMSO were added to the reaction 
buffer, consisting of 50 mM Tris-HCl pH 8.5, 75 
mM potassium acetate, 10 μM magnesium 
acetate, 1 mM ATP and 10 % glycerol (w/v). 
Reactions were started by the addition of the 
ATPase TrwD (2 µM). 
Conjugation assays. Conjugation frequencies 
(CF) were obtained with a fluorescence-based 
assay previously described (7). Strain DH5α 
carrying the conjugative plasmid pJC01, which 
expresses GFP under the control of T7 promoter, 












was used as a donor. A streptomycin-resistant 
derivative of E. coli BL21 (DE3), expressing T7 
RNA polymerase from the inserted phage, was 
used as recipient strain. Both strains at stationary 
phase were concentrated 4-fold and mixed at a 1:1 
ratio. Mixture samples (10 µl) were spotted onto 
96-well microtiter plates (Bioster a.s.) containing 
150 µl LB, 1 % agar, 1 mM IPTG and different 
concentrations of fatty acids, with the help of a 
Biomek 3000 liquid-handling robot (Beckman 
Coulter). After incubation at 37 ºC for 6 h to allow 
conjugation, cells were resuspended in Phosphate-
Buffered Saline (PBS) and transferred to a new 
plate. The optical density at 600 nm (OD600) and 
GFP emission were measured in a Victor3 multi-
label counter (PerkinElmer). CF was calculated as 
the ratio of absolute fluorescence emitted by 
transconjugant cells and the total number of cells 
(OD600). Relative CF in the presence of a 
compound was determined as a fraction of the CF 
observed in controls performed in the absence of 
the inhibitor. To reproduce the conditions, 
equivalent volumes of solvent (DMSO) were 
added to control samples. 
Molecular modelling and ligand docking. An 
atomic model of TrwD was generated by 
molecular threading using as template the atomic 
coordinates of B. suis VirB11 (2gza.pdb) (14), as 
previously described (28). The structural 
coordinates of palmitic acid, 2-HDA and 2-BP 
acid were retrieved from PubChem database 
(https://pubchem.ncbi.nlm.nih.gov/) and prepared 
for docking as previously described (8). Files 
containing the atomic coordinates of the TrwD 
model and the fatty acids were submitted to the 
SwissDock server (http://www.swissdock.ch/) to 
run blind docking. Results were examined with 
UCSF Chimera. Binding poses with the best Full-
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Figure 1. Composition of phospholipid fatty acids and free fatty acids in E. coli after exposure to 
2-HDA. E. coli cells were grown at 37 °C for 18 h in Luria Broth (LB) containing 50 µg/mL 2-HDA 
(treated), or in its absence (untreated).  Fatty acids were eluted, converted to methyl-esters and analyzed 
by Gas Chromatography – Mass Spectrometry (GC-MS), as described in materials and methods. Bars 
represent the relative abundance of different fatty acids obtained from three separated experiments (mean 
± SD). Fatty acid nomenclature indicates the number of carbons followed by the number of double 
bonds. 2-HDA refers to 2-hexadecynoic acid. 
 
  
















Figure 2. TrwD binding to 14C-labeled palmitic acid and palmitoyl-CoA.  (A). TrwD (80 µM) was 
incubated at increasing 14C-labeled palmitic acid ratios (1:0.25, 1:0.5, 1:0.75 and 1:1 protein:palmitic 
acid molar ratios, respectively). Lane C1 corresponds to TrwD (80 µM) in the absence of fatty acids. 
Lane C2 is also a control experiment in which an alien protein, TrwA (80 µM), was incubated with 14C-
palmitic acid at a 1:1 protein:palmitic acid molar ratio. (B)  TrwD (80 µM) was incubated at increasing 
14C-labeled palmitoyl-CoA ratios (1:0.5, 1:0.75 and 1:1 protein: palmitoyl CoA molar ratios, 
respectively). Lane C1 corresponds to 14C-palmitoyl CoA (80 µM) in the absence of any protein. Lane 
C2, as in panel A, corresponds to TrwA (80 µM) incubated with 14C-palmitoyl CoA (80 µM). Lane C1 
and C2 radioactivity signals at the front of the gel correspond to free 14C-labeled palmitoyl CoA. In both 
cases, protein-fatty acid complexes were analyzed by Native-PAGE and radiolabeled images were 
obtained after overnight exposure, as described in materials and methods.  (C) TrwD (80 µM; Lane D1) 
and TrwA (80 µM; Lane D2) were analyzed by Coomassie Brilliant Blue-stained Native-PAGE, as 
described in materials and methods. 
 
 



















Figure 3. Determination of the kinetic parameters of inhibition by 2-bromopalmitic acid. ATP 
hydrolysis by TrwD (2 µM) was measured at increasing concentrations of 2-bromopalmitic acid (white 
circles) and compared with the values obtained at increasing concentrations of 2-HDA (black circles) 
(8). Data were fitted to a Hill inhibition equation (error bars: SD). 
 
  
















Figure 4. Blind docking of fatty acids into the molecular model of TrwD. Blind docking predictions 
between a molecular model of monomeric TrwD and fatty acid ligands (palmitic and 2-bromopalmitic 
acid) were performed using the EADock dihedral spacing sampling engine of the Swiss-dock server 
(32). Both fatty acids fit into a pocket located at the interface between the N-terminal domain (NTD, 
pink) and the linker region (light orange), which connects the NTD with the catalytic C-terminal domain 
(CTD, brown).  Upper left and right panels correspond to the same view in cartoon and surface 
representation, respectively. The carbon chains of both fatty acids have a similar orientation (colors blue 
and yellow for palmitic and 2-bromopalmitic acids, respectively).  However, the carboxylic group of the 
2-bromo derivative is buried inside a pocket formed by the NTD and the linker domain of the protein, 
being the bromine atom (dark green) stabilized by electrostatic basic residues  located in the region. On 
the contrary, the carboxylic group of the palmitic acid (red) is 120 degrees apart, out of the linker region. 
The panel on the right shows a zoom of the binding pocket, in which the basic residues surrounding the 
carboxylic groups of the fatty acids are better appreciated. For more clarity see also movie 1S in 
Supporting information.  
 
  

















Figure 5. 2-Bromopalmitic and palmitic acids compete for the same TrwD binding site. TrwD 
ATPase rates (2 µM) were measured as described in materials and methods, at increasing concentrations 
of palmitic acid (dark circles), 2-bromopalmitic acid (white circles) and mixtures of both fatty acids 
consisting of a fixed concentration of palmitic acid (500 µM) and increasing concentrations of 2-
bromopalmitate (dark triangles). In the latter case, protein sample was first incubated with palmitic acid 
for 5 min, and then 2-bromopalmitic acid was added at the indicated concentrations. Data were fitted to 
a sigmoidal Hill equation for inhibition (error bars: SD).  
 
  

















Figure 6. R388 conjugation frequency (CF) in the presence of increasing concentrations of 2-
bromopalmitic acid. Bacterial conjugation experiments were performed by a fluorescence-based assay 
as described in materials and methods. A) Values represent the mean CF ± SD from at least four 
independent experiments, relative to a positive control in the absence of inhibitor (100 %). Panel B (inset 
figure) shows the relative CF from individual experiments in the presence of 2-bromopalmitic acid (50 
µM) (black circles) and a mixture of both palmitic (500 µM) and 2-bromopalmitic acids (50 µM) (grey 
squares). Horizontal and vertical bars represent the mean ± SD of each group of data. Statistical 
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